Histone deacetylases are able to catalyze the hydrolysis of N-acetyl lysine residues of histones which package
chromosomal DNA. Therefore they play an important role in mediating gene expression and cell proliferation. HDAC inhibitors
have not only shown promise as antiparasitic, antineurodegenerative, antirheumatologic agents and immunosuppressant,
but as potent anticancer agents by inducing cell cycle arrest, differentiation and apoptosis. This review highlights
recent development in design, synthesis and biological evaluation of HDAC inhibitors for cancer therapy.
Keywords: Antitumor drugs, cancer therapy, cyclic peptide, drug discovery, epigenetic regulation, histone deacetylase, hdac
isoforms, histone deacetylase inhibitors, hybrid compounds, multi-targeted inhibitor.
open access plus
Rights & PermissionsPrintExport